SynthesisInternational archives of allergy and immunology2026
House Dust Mite Sublingual Immunotherapy for Allergic Rhinoconjunctivitis: Comprehensive Review and Meta-Analytical Evidence.
Synthesis in International archives of allergy and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of house dust mite allergen immunotherapy in allergic rhinitis: a network meta-analysis based on component-resolved classification.Frontiers in immunology · 2026Pooled it
Corrections and comments
- Erratum issuedErratum.2026
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHouse dust mites (HDM) are a primary trigger of allergic rhinoconjunctivitis (ARC), a common condition associated with substantial symptom burden and impaired quality of life. Although sublingual immunotherapy (SLIT) with HDM extracts has shown therapeutic potential, its overall efficacy and safety profile in adults and adolescents with ARC remain incompletely defined. We aimed to assess the efficacy and safety of HDM SLIT in adults and adolescents with ARC.
methodsWe conducted a systematic search of PubMed, Scopus, Web of Science (WOS), and Cochrane CENTRAL databases up to May 2025. We included studies comparing HDM SLIT to placebo or pharmacotherapy. The main efficacy outcomes were the combined symptom and medication score (CSMS), rhinitis symptom score (RSS), rhinitis medication score (RMS), and rhinoconjunctivitis quality of life questionnaire. Safety was assessed by analyzing treatment-related adverse events (AEs), serious, severe, and local AEs. A random-effects model was used to pool standardized mean differences (SMD) and risk ratios (RR).
resultsA total of 45 studies involving 30,288 participants were included in the systematic review, with 28 providing data for meta-analysis. SLIT significantly improved multiple efficacy outcomes, including the RSS and RMS, with pooled SMD and 95% confidence interval (CI) (-0.98 [-1.65, -0.31], p < 0.001) and (-1.00 [-1.80, -0.20], p = 0.01), respectively. SLIT was associated with a greater risk of treatment-related AEs, with a pooled RR and 95% CI (1.16 [1.02, 1.33], p = 0.02), which were predominantly mild, local, and transient.
conclusionThis study confirms that standardized HDM SLIT is an effective and safe disease-modifying therapy for adults and adolescents with ARC. It provides clinically meaningful reductions in symptoms and medication use and improves quality of life. The favorable safety profile supports its use as a foundational treatment in the management of HDM-induced ARC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.